A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Effects of Whole‐Body Cryotherapy Combined With Conventional Obesity Management Versus Obesity Management Alone: A Clinical Trial




TekijätKarppinen, Jari E.; Suojanen, Laura; Heinonen, Sini; Kaye, Sanna; van der Kolk, Birgitta W.; White, James W.; Orava, Janne; Lee, Seung Hyuk T.; Dillon, Eugené; Muniandy, Maheswary; Rissanen, Aila; le Roux, Carel W.; Docherty, Neil; Pajukanta, Päivi; Virtanen, Kirsi A.; Pietiläinen, Kirsi H.

KustantajaJohn Wiley & Sons

Julkaisuvuosi2025

JournalObesity

Artikkelin numerooby.70019

ISSN1930-7381

eISSN1930-739X

DOIhttps://doi.org/10.1002/oby.70019

Verkko-osoitehttps://doi.org/10.1002/oby.70019

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/500041107


Tiivistelmä
Objective

To investigate whether whole-body cryotherapy (WBC) enhances weight loss, brown adipose tissue (BAT) activation, and metabolic outcomes during obesity management.

Methods

Nineteen adults with obesity were assigned to a 12-month lifestyle-based obesity management intervention with 28 WBC sessions (−110°C, 3–4 min, ~2 × week) over the first 5 months (CRYO, n = 10) or the intervention without WBC (CON, n = 9). The primary outcome was weight loss (5 and 12 months). Secondary outcomes included BAT glucose uptake and whole-body energy expenditure during cold stimulation (5 months), clinical parameters, subcutaneous adipose tissue transcriptomics, and skeletal muscle proteomics (5 and 12 months).

Results

Weight loss in the CRYO group was 11.9% at 5 months and 9.9% at 12 months, compared to 11.5% and 8.0% in the CON group (p ≥ 0.54 for between-group differences). No significant between-group differences appeared in BAT glucose uptake, energy expenditure, adipose tissue transcriptomics, or skeletal muscle proteomics changes. However, at 5 months, the CRYO group showed greater reductions in fasting glucose (0.41 mmol/L, p = 0.026) and LDL cholesterol (0.44 mmol/L, p = 0.034).

Conclusions

WBC did not significantly enhance weight loss, activate BAT, or alter most metabolic responses during conventional obesity management. Further research is needed to confirm whether WBC benefits glucose and cholesterol metabolism.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This study was supported by Research Council of Finland (grant numbers 259926, 265204, 292839, 314456, 335446, 335443, 314383, 272376, 266286, 361956 and 338417); Finnish Medical Foundation; Gyllenberg Foundation; Novo Nordisk Foundation (grant numbers NNF20OC0060547, NNF17OC0027232, NNF10OC1013354, NNF23SA0083953); Finnish Diabetes Research Foundation; Instrumentarium Science Foundation; Paulo Foundation; Orion Foundation; Sigrid Juselius Foundation; University of Helsinki and Helsinki University Hospital; and Government Research Funds. The work was also supported by the European Union (EU FP7 project 278373; DIABAT).


Last updated on 2025-23-09 at 17:15